HealthEquity, Inc. (NASDAQ:HQY) Director Stuart B. Parker Sells 25,000 Shares of Stock

HealthEquity, Inc. (NASDAQ:HQY) Director Stuart B. Parker sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $96.72, for a total value of $2,418,000.00. Following the transaction, the director now directly owns 19,061 shares of the company’s stock, valued at approximately $1,843,579.92. This trade represents a 56.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

HealthEquity Stock Performance

NASDAQ:HQY opened at $95.62 on Friday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 3.20. HealthEquity, Inc. has a fifty-two week low of $62.10 and a fifty-two week high of $105.82. The company has a market cap of $8.29 billion, a price-to-earnings ratio of 87.72, a PEG ratio of 1.10 and a beta of 0.55. The stock has a fifty day moving average price of $94.06 and a 200-day moving average price of $84.19.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. JMP Securities lifted their price target on shares of HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a research note on Tuesday. BTIG Research raised their price target on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Bank of America upped their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Mizuho initiated coverage on shares of HealthEquity in a report on Wednesday, December 4th. They set an “outperform” rating and a $126.00 target price for the company. Finally, The Goldman Sachs Group initiated coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 price target on the stock. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $110.71.

Institutional Investors Weigh In On HealthEquity

Several institutional investors and hedge funds have recently bought and sold shares of HQY. Holocene Advisors LP bought a new position in HealthEquity in the third quarter valued at about $1,246,000. GSA Capital Partners LLP acquired a new position in HealthEquity during the 3rd quarter worth approximately $638,000. Vaughan Nelson Investment Management L.P. lifted its stake in HealthEquity by 36.7% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after purchasing an additional 226,563 shares during the last quarter. Natixis Advisors LLC boosted its position in HealthEquity by 29.8% in the third quarter. Natixis Advisors LLC now owns 209,175 shares of the company’s stock valued at $17,122,000 after buying an additional 48,009 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its stake in shares of HealthEquity by 29.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company’s stock worth $5,535,000 after buying an additional 14,573 shares during the last quarter. Institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.